SCYNEXIS, Inc. (LON:0L49)

Market Cap	19.67M
Revenue (ttm)	2.18M
Net Income (ttm)	-18.82M
Shares Out	n/a
EPS (ttm)	-0.38
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	25
Average Volume	2,560
Open	0.6209
Previous Close	0.6301
Day's Range	0.6208 - 0.6256
52-Week Range	0.5680 - 1.4710
Beta	n/a
RSI	41.08
Earnings Date	Mar 12, 2026

About SCYNEXIS

SCYNEXIS, Inc., a biotechnology company, develops medicines to overcome and prevent difficult-to-treat and drug-resistant infections in the United States. It offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis (VVC) and recurrent VVC. The company’s lead product candidate is Ibrexafungerp, a drug for the treatment of invasive candidiasis and/or candidemia, refractory invasive fungal infections, invasive aspergillosis, VVC, and recurrent VVC. It also develops SCY-247 to treat systemic fungal diseases. The company has lic...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1999
• Employees: 28
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0L49

Financial Performance

Financial numbers in USD